Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) With Bevacizumab and Irinotecan for Malignant Glioma
Status:
Completed
Trial end date:
2009-07-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different
ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and
help kill them or carry tumor-killing substances to them. Bevacizumab may also block blood
flow to the tumor. Drugs used in chemotherapy, such as irinotecan, work in different ways to
stop the growth of tumor cells, either by killing the cells or by stopping them from
dividing. Giving bevacizumab together with irinotecan may kill more tumor cells. Diagnostic
procedures, such as MRI, may help doctors predict a patient's response to treatment and help
plan the best treatment.
PURPOSE: This phase II trial is studying how well giving bevacizumab together with irinotecan
works in treating patients with recurrent malignant glioma and how well MRI predicts response
to treatment.